Anthonly S. Marucci net worth and biography

Anthonly Marucci Biography and Net Worth

President & CEO of Celldex Therapeutics

Mr. Marucci was appointed President and Chief Executive Officer of Celldex in September 2008 and as a director of Celldex in December 2008. Since May 2003, Mr. Marucci has held a number of roles with Celldex, including as a founder, Vice President, Chief Financial Officer, Treasurer and Secretary. In addition, he was Treasurer of Medarex, Inc. (now a part of Bristol-Myers Squibb Co.) from December 1998 to March 2004. Mr. Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. Since May 2021, Mr. Marucci serves as a member of the board of directors of Genenta Science S.p.A., a publicly held biopharmaceutical company. Mr. Marucci is a member of the Board of Trustees of BioNJ Inc. and also served as its Treasurer through 2010. Mr. Marucci is also a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci received his M.B.A. from Columbia University and his M.H.L. from Brown University.

How do I contact Anthonly S. Marucci?: The corporate mailing address for Mr. Marucci and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Anthonly S. Marucci's contact information.
Has Anthonly S. Marucci been buying or selling shares of Celldex Therapeutics?: Anthonly S. Marucci has not been actively trading shares of Celldex Therapeutics in the last ninety days. Learn More on Anthonly S. Marucci's trading history.
Who are Celldex Therapeutics' active insiders?: Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.
Are insiders buying or selling shares of Celldex Therapeutics?: In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company. Learn More about insider trades at Celldex Therapeutics.
Information on this page was last updated on 11/11/2024.

Anthonly S. Marucci Insider Trading History at Celldex Therapeutics

Anthonly S. Marucci Buying and Selling Activity at Celldex Therapeutics

Celldex Therapeutics Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Today's Range

Now: $26.04

$25.69

$26.47

50 Day Range

MA: $27.19

$23.31

$31.32

2 Week Range

Now: $26.04

$22.93

$53.18

Volume

705,364 shs

Average Volume

887,486 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.